Check-Cap Ltd. (NASDAQ: CHEK) is a clinical-stage medical device company focused on the development of non-invasive screening technologies for colorectal cancer. The company’s lead product, the C-Scan® system, is designed to provide a full-colonic 360° visualization by combining an ingestible X-ray emitting capsule with an external detector array and proprietary image reconstruction algorithms. Intended as a minimally invasive alternative to traditional colonoscopy, the C-Scan system aims to improve patient comfort and compliance while maintaining high sensitivity for detecting polyps and early-stage lesions.
The C-Scan procedure involves the patient ingesting the capsule, which passes naturally through the gastrointestinal tract. During its transit, the capsule emits low-dose X-rays that are captured by detectors worn externally around the abdomen. Data collected by the system are then processed by software to generate high-resolution, panoramic images of the colon lining. This approach seeks to address limitations of stool-based tests and virtual colonoscopy, offering clinicians detailed anatomical views without sedation or insufflation.
Founded in Israel, Check-Cap maintains its headquarters in Caesarea along with operations in the United States, where it conducts clinical trials and regulatory activities. The company has completed multiple early-stage studies and has been advancing toward pivotal trials required for regulatory clearances in both European and U.S. markets. Check-Cap’s development strategy includes collaborations with leading gastroenterology centers to validate clinical efficacy and support future commercial rollout.
Check-Cap is led by a management team with extensive experience in medical imaging, device development and gastroenterology. The company continues to advance its C-Scan platform through ongoing research, regulatory engagement and strategic partnerships, aiming to transform colorectal cancer screening by offering a patient-friendly solution with broad applicability in routine preventive care.
AI Generated. May Contain Errors.
Free CHEK Stock Alerts